Principal Financial Group Inc Biomarin Pharmaceutical Inc Transaction History

Principal Financial Group Inc

$1.66 Trillion
Q3 2024

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	SELL	$69.02 - $93.84 $13.2 Million - $18 Million	-191,421 Reduced 29.47%	458,039 $32.2 Million
Q2 2024 Jul 29, 2024	BUY	$74.43 - $92.22 $45.9 Million - $56.8 Million	616,301 Added 1858.62%	649,460 $53.5 Million
Q1 2024 Apr 29, 2024	BUY	$83.81 - $99.0 $289,395 - $341,847	3,453 Added 11.62%	33,159 $2.9 Million
Q4 2023 Feb 07, 2024	SELL	$76.22 - $98.51 $220,885 - $285,481	-2,898 Reduced 8.89%	29,706 $2.86 Million
Q3 2023 Nov 02, 2023	BUY	$85.07 - $94.48 $101,233 - $112,431	1,190 Added 3.79%	32,604 $2.88 Million
Q2 2023 Aug 07, 2023	SELL	$86.68 - $100.3 $287,430 - $332,594	-3,316 Reduced 9.55%	31,414 $2.72 Million
Q1 2023 May 09, 2023	BUY	$87.74 - $117.27 $78,702 - $105,191	897 Added 2.65%	34,730 $3.38 Million
Q4 2022 Feb 09, 2023	SELL	$80.93 - $108.63 $1.94 Million - $2.61 Million	-24,014 Reduced 41.51%	33,833 $3.5 Million
Q3 2022 Nov 09, 2022	BUY	$82.16 - $96.94 $1.1 Million - $1.3 Million	13,372 Added 30.07%	57,847 $4.9 Million
Q2 2022 Aug 10, 2022	BUY	$71.48 - $86.85 $85,275 - $103,612	1,193 Added 2.76%	44,475 $3.69 Million
Q1 2022 May 09, 2022	BUY	$74.28 - $92.69 $335,522 - $418,680	4,517 Added 11.65%	43,282 $3.34 Million
Q4 2021 Feb 09, 2022	SELL	$71.72 - $91.47 $1.18 Million - $1.51 Million	-16,502 Reduced 29.86%	38,765 $3.42 Million
Q3 2021 Nov 09, 2021	SELL	$74.77 - $85.47 $478,154 - $546,580	-6,395 Reduced 10.37%	55,267 $4.27 Million
Q2 2021 Aug 10, 2021	SELL	$75.51 - $84.79 $27,561 - $30,948	-365 Reduced 0.59%	61,662 $5.15 Million
Q1 2021 May 10, 2021	BUY	$74.73 - $90.69 $242,872 - $294,742	3,250 Added 5.53%	62,027 $4.68 Million
Q4 2020 Feb 08, 2021	BUY	$72.61 - $90.2 $918,371 - $1.14 Million	12,648 Added 27.42%	58,777 $5.15 Million
Q3 2020 Nov 06, 2020	SELL	$71.87 - $131.03 $313,353 - $571,290	-4,360 Reduced 8.64%	46,129 $3.51 Million
Q2 2020 Aug 05, 2020	BUY	$79.55 - $124.22 $613,250 - $957,611	7,709 Added 18.02%	50,489 $6.23 Million
Q1 2020 May 12, 2020	BUY	$71.37 - $96.85 $123,969 - $168,228	1,737 Added 4.23%	42,780 $3.62 Million
Q4 2019 Feb 05, 2020	BUY	$64.27 - $86.37 $127,383 - $171,185	1,982 Added 5.07%	41,043 $3.47 Million
Q3 2019 Nov 13, 2019	SELL	$67.4 - $85.11 $127,655 - $161,198	-1,894 Reduced 4.62%	39,061 $2.63 Million
Q2 2019 Aug 12, 2019	BUY	$80.35 - $93.9 $45,638 - $53,335	568 Added 1.41%	40,955 $3.51 Million
Q1 2019 May 10, 2019	BUY	$84.2 - $98.62 $242,496 - $284,025	2,880 Added 7.68%	40,387 $3.59 Million
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $521,631 - $690,409	-6,509 Reduced 14.79%	37,507 $3.19 Million
Q3 2018 Nov 14, 2018	BUY	$93.92 - $105.72 $161,354 - $181,626	1,718 Added 4.06%	44,016 $4.27 Million
Q2 2018 Aug 13, 2018	BUY	$76.01 - $99.03 $194,433 - $253,318	2,558 Added 6.44%	42,298 $0
Q1 2018 May 14, 2018	BUY	$77.67 - $92.63 $82,796 - $98,743	1,066 Added 2.76%	39,740 $3.22 Million
Q4 2017 Feb 13, 2018	BUY	$80.76 - $95.13 $982,849 - $1.16 Million	12,170 Added 45.92%	38,674 $3.45 Million
Q3 2017 Nov 02, 2017	BUY	$80.6 - $94.95 $2.14 Million - $2.52 Million	26,504	26,504 $2.47 Million

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

Black Rock Inc. New York, NY

22.7M
Shares

$1.51 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

19.3M
Shares

$1.28 Billion
0.02% of portfolio
Primecap Management CO Pasadena, CA

18.9M
Shares

$1.25 Billion
0.99% of portfolio
Dodge & Cox San Francisco, CA

13.9M
Shares

$921 Million
0.59% of portfolio
Capital Research Global Investors Los Angeles, CA

10.5M
Shares

$696 Million
0.16% of portfolio

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account